{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T09:06:42Z","timestamp":1791104802821,"version":"4.1.0"},"reference-count":38,"publisher":"Elsevier BV","issue":"8-9","license":[{"start":{"date-parts":[[2010,8,1]],"date-time":"2010-08-01T00:00:00Z","timestamp":1280620800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2010,8,1]],"date-time":"2010-08-01T00:00:00Z","timestamp":1280620800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annales de Dermatologie et de V\u00e9n\u00e9r\u00e9ologie"],"published-print":{"date-parts":[[2010,8]]},"DOI":"10.1016\/j.annder.2010.04.016","type":"journal-article","created":{"date-parts":[[2010,6,20]],"date-time":"2010-06-20T21:02:27Z","timestamp":1277067747000},"page":"523-531","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Prise en charge des lymphomes B cutan\u00e9s\u00a0: recommandations du Groupe fran\u00e7ais d\u2019\u00e9tude des lymphomes cutan\u00e9s"],"prefix":"10.1016","volume":"137","author":[{"given":"F.","family":"Grange","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"D\u2019Incan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Ortonne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Dalac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Laroche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Beylot-Barry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.-H.","family":"Delfau-Larue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Vergier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Bagot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.annder.2010.04.016_bib1","doi-asserted-by":"crossref","first-page":"3768","DOI":"10.1182\/blood-2004-09-3502","article-title":"WHO-EORTC classification for cutaneous lymphomas","volume":"105","author":"Willemze","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.annder.2010.04.016_bib2","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1182\/blood-2008-04-152850","article-title":"European Organization for Research and Treatment of Cancer and International Society for Cutaneous Lymphoma consensus recommendations for the management of cutaneous B-cell lymphomas","volume":"112","author":"Senff","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.annder.2010.04.016_bib3","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1111\/j.1365-2133.2008.08659.x","article-title":"Asymptomatic bone marrow involvement in patients presenting with cutaneous marginal zone-B cell lymphoma","volume":"159","author":"Bathelier","year":"2008","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.annder.2010.04.016_bib4","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1111\/j.1365-2141.2008.07159.x","article-title":"Results of bone marrow aspiration in 275\u00a0patients with histologival features that suggest an indolent form of cutaneous B-cell lymphoma","volume":"142","author":"Senff","year":"2008","journal-title":"Br J Haematol"},{"key":"10.1016\/j.annder.2010.04.016_bib5","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1007\/s11307-007-0127-y","article-title":"FDG-PET\/CT in the evalutation of cutaneous T-cell lymphoma","volume":"10","author":"Kuo","year":"2008","journal-title":"Mol Imaging Biol"},{"key":"10.1016\/j.annder.2010.04.016_bib6","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1002\/1097-0142(19910501)67:9<2311::AID-CNCR2820670918>3.0.CO;2-0","article-title":"Primary cutaneous B-cell lymphoma: a unique type of low-grade lymphoma. Clinicopathologic and immunologic study of 83\u00a0cases","volume":"67","author":"Santucci","year":"1991","journal-title":"Cancer"},{"key":"10.1016\/j.annder.2010.04.016_bib7","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1001\/archderm.141.9.1139","article-title":"Primary cutaneous marginal zone B-cell lymphoma: clinical and therapeutic features in 50\u00a0cases","volume":"141","author":"Hoefnagel","year":"2005","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.annder.2010.04.016_bib8","doi-asserted-by":"crossref","first-page":"3602","DOI":"10.1200\/JCO.2001.19.16.3602","article-title":"Prognostic factors in primary cutaneous large B-cell lymphomas: a European Multicenter Study","volume":"19","author":"Grange","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.annder.2010.04.016_bib9","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1001\/archderm.143.12.1520","article-title":"Results of radiotherapy in 153\u00a0primary cutaneous B-cell lymphomas classified according to the WHO-EORTC classification","volume":"153","author":"Senff","year":"2007","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.annder.2010.04.016_bib10","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1200\/JCO.2004.08.044","article-title":"Primary cutaneous B-cell lymphoma treated with radiotherapy: a comparison of the EORTC and the WHO classification systems","volume":"22","author":"Smith","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.annder.2010.04.016_bib11","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1200\/JCO.1999.17.8.2471","article-title":"Treatment of multifocal primary cutaneous B-cell lymphoma: a clinical follow-up study of 29\u00a0patients","volume":"17","author":"Bekkenk","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.annder.2010.04.016_bib12","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1200\/JCO.2005.03.6285","article-title":"Prognostic factors in primary cutaneous B-cell lymphoma: the Italian study group for cutaneous lymphomas","volume":"24","author":"Zinzani","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.annder.2010.04.016_bib13","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.ijrobp.2008.06.1918","article-title":"Low-dose palliative radiotherapy for cutaneous B- and T-cell lymphomas","volume":"74","author":"Neelis","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.annder.2010.04.016_bib14","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/S0190-9622(97)80405-7","article-title":"Borrelia burgdorferi-associated primary cutaneous B cell lymphoma: complete clearing of skin lesions after antibiotic pulse therapy or intralesional injection of interferon alfa-2a","volume":"36","author":"K\u00fctting","year":"1997","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.annder.2010.04.016_bib15","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S0046-8177(00)80233-6","article-title":"Eradication of Borrelia burgdorferi infection in primary marginal zone B-cell lymphoma of the skin","volume":"31","author":"Roggero","year":"2000","journal-title":"Hum Pathol"},{"key":"10.1016\/j.annder.2010.04.016_bib16","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1067\/mjd.2002.120475","article-title":"Borrelia burgdorferi infection simulating a primary cutaneous B-cell lymphoma","volume":"47","author":"Grange","year":"2002","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.annder.2010.04.016_bib17","first-page":"1273","article-title":"16th consensus conference on treatment of infectious diseases. Lyme disease (borreliosis) diagnostic approach, therapy and prevention","volume":"163","year":"2007","journal-title":"Rev Neurol"},{"key":"10.1016\/j.annder.2010.04.016_bib18","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.jaad.2005.01.093","article-title":"Treatment of primary cutaneous B-cell lymphoma with rituximab","volume":"52","author":"Fink-Puches","year":"2005","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.annder.2010.04.016_bib19","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1080\/10428190600688099","article-title":"Cutaneous B-cell lymphoma responds to rituximab: a report of 5\u00a0cases and review of the literature","volume":"47","author":"Gitelson","year":"2006","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.annder.2010.04.016_bib20","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1111\/j.1600-0609.2006.00720.x","article-title":"Favorable outcome of primary cutaneous marginal zone lymphoma treated with intralesional rituximab","volume":"77","author":"Kyrtsonis","year":"2006","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.annder.2010.04.016_bib21","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1111\/j.1365-2133.2006.07523.x","article-title":"Intralesional and intravenous treatment of cutaneous B-cell lymphomas with the monoclonal anti-CD20\u00a0antibody rituximab: report and follow-up of 8\u00a0cases","volume":"155","author":"Kerl","year":"2006","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.annder.2010.04.016_bib22","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1111\/j.1365-2133.2005.06659.x","article-title":"Systemic 8\u00a0cycles anti-CD20\u00a0monoclonal antibody (rituximab) therapy in primary cutaneous B-cell lymphomas. an applicational observation","volume":"153","author":"Gellrich","year":"2005","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.annder.2010.04.016_bib23","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1093\/annonc\/mdn636","article-title":"Rituximab monotherapy for primary cutaneous B-cell lymphoma: response and follow-up in 16\u00a0patients","volume":"20","author":"Valencak","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annder.2010.04.016_bib24","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1046\/j.1365-2133.2001.04241.x","article-title":"Intralesional rituximab for cutaneous lymphoma","volume":"144","author":"Paul","year":"2001","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.annder.2010.04.016_bib25","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/j.jaad.2008.08.005","article-title":"Indolent primary cutaneous B-cell lymphoma: experience using systemic rituximab","volume":"59","author":"Morales","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.annder.2010.04.016_bib26","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1080\/10428190802258923","article-title":"Yttrium-90\u00a0ibritumomab tiuxetan radioimmunotherapy in primary cutaneous B-cell lymphomas: first results of a prospective, monocentre study","volume":"49","author":"Maza","year":"2008","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.annder.2010.04.016_bib27","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1001\/archderm.143.9.1144","article-title":"Primary cutaneous large B-cell lymphoma, leg type: clinicopathologic features and prognostic analysis in 60\u00a0cases","volume":"143","author":"Grange","year":"2007","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.annder.2010.04.016_bib28","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1111\/j.1600-0609.2008.01197.x","article-title":"Efficacy and safety of pegylated liposomal doxorubicin in primary cutaneous B-cell lymphomas and comparison with the commonly used therapies","volume":"82","author":"Pulini","year":"2009","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.annder.2010.04.016_bib29","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJMoa011795","article-title":"CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large B-cell lymphoma","volume":"346","author":"Coiffier","year":"2002","journal-title":"N Eng J Med"},{"key":"10.1016\/j.annder.2010.04.016_bib30","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1200\/JCO.2006.10.5957","article-title":"Lymphoma in older patients","volume":"25","author":"Thieblemont","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.annder.2010.04.016_bib31","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1001\/archdermatol.2009.23","article-title":"Treatment of primary cutaneous diffuse large B-cell lymphomas, leg type, with age-adapted combinations of chemotherapies and rituximab","volume":"145","author":"Grange","year":"2009","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.annder.2010.04.016_bib32","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1001\/archderm.1996.03890350042008","article-title":"Primary cutaneous large B-cell lymphomas of the legs. A distinct type of cutaneous B-cell lymphoma with an intermediate prognosis","volume":"132","author":"Vermeer","year":"1996","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.annder.2010.04.016_bib33","doi-asserted-by":"crossref","first-page":"2491","DOI":"10.1182\/blood-2005-03-1175","article-title":"Primary cutaneous large B-cell lymphomas: clinicopathologic features, classification, and prognostic factors in a large series of patients","volume":"106","author":"Kodama","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.annder.2010.04.016_bib34","first-page":"30","article-title":"Pronostic des lymphomes B cutan\u00e9s primitifs","volume":"129","author":"Grange","year":"2002","journal-title":"Ann Dermatol Venereol"},{"key":"10.1016\/j.annder.2010.04.016_bib35","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1111\/j.1365-2133.2007.08239.x","volume":"157","author":"Senff","year":"2007","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.annder.2010.04.016_bib36","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1182\/blood-2006-10-054601","article-title":"TNM classification for primary cutaneous lymphomas other than MF\/SS: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the Cutaneous Lymphoma Task Force of the European Organization of Research and Treatment of Cancer (EORTC)","volume":"110","author":"Kim","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.annder.2010.04.016_bib37","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1200\/JCO.2006.09.6396","article-title":"Reclassification of 300\u00a0primary cutaneous B-Cell lymphomas according to the new WHO-EORTC classification for cutaneous lymphomas: comparison with previous classifications and identification of prognostic markers","volume":"25","author":"Senff","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.annder.2010.04.016_bib38","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1001\/archdermatol.2009.345","article-title":"Combined treatment with rituximab and anthracycline-containing chemotherapy for primary cutaneous large B-cell lymphomas, leg type, in elderly patients","volume":"146","author":"Guyot","year":"2010","journal-title":"Arch Dermatol"}],"container-title":["Annales de Dermatologie et de V\u00e9n\u00e9r\u00e9ologie"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0151963810002279?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0151963810002279?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T10:56:45Z","timestamp":1758970605000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0151963810002279"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,8]]},"references-count":38,"journal-issue":{"issue":"8-9","published-print":{"date-parts":[[2010,8]]}},"alternative-id":["S0151963810002279"],"URL":"https:\/\/doi.org\/10.1016\/j.annder.2010.04.016","relation":{},"ISSN":["0151-9638"],"issn-type":[{"value":"0151-9638","type":"print"}],"subject":[],"published":{"date-parts":[[2010,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prise en charge des lymphomes B cutan\u00e9s\u00a0: recommandations du Groupe fran\u00e7ais d\u2019\u00e9tude des lymphomes cutan\u00e9s","name":"articletitle","label":"Article Title"},{"value":"Annales de Dermatologie et de V\u00e9n\u00e9r\u00e9ologie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annder.2010.04.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2010 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}